Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.
When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.
Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.
For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U. S. in 2021 (a rate of 2.4 per 100,000 persons). In the U. S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.
For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.
However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.
For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany - lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.
The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S. A., and Sun Pharmaceutical Industries Ltd.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.
When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.
Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.
For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U. S. in 2021 (a rate of 2.4 per 100,000 persons). In the U. S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.
For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.
However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.
For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany - lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.
The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S. A., and Sun Pharmaceutical Industries Ltd.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Azoles
- Polyenes
- Others
By Distribution Channel
- Hospital and Clinical Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Formulation
- Tablets
- Ointment
- Powder
- Liquid
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- Sanofi
- Merck and Company
- GSK
- johnson and johnson md&d
- Abbott Laboratories
- CELON LABORATORIES LIMITED
- Sun Pharmaceuticals Ltd
- Astellas Pharma Inc.
- Cipla Ltd
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: BLASTOMYCOSIS MARKET, BY FORMULATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Tablets
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Ointment
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Powder
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Liquid
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
CHAPTER 5: BLASTOMYCOSIS MARKET, BY DRUG TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Azoles
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Polyenes
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital and Clinical Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Online Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Retail Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: BLASTOMYCOSIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Formulation
7.2.3 North America Market size and forecast, by Drug Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Formulation
7.2.5.1.3 Market size and forecast, by Drug Type
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Formulation
7.2.5.2.3 Market size and forecast, by Drug Type
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Formulation
7.2.5.3.3 Market size and forecast, by Drug Type
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Formulation
7.3.3 Europe Market size and forecast, by Drug Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Formulation
7.3.5.1.3 Market size and forecast, by Drug Type
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Formulation
7.3.5.2.3 Market size and forecast, by Drug Type
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Formulation
7.3.5.3.3 Market size and forecast, by Drug Type
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Formulation
7.3.5.4.3 Market size and forecast, by Drug Type
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Formulation
7.3.5.5.3 Market size and forecast, by Drug Type
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Formulation
7.3.5.6.3 Market size and forecast, by Drug Type
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Formulation
7.4.3 Asia-Pacific Market size and forecast, by Drug Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Formulation
7.4.5.1.3 Market size and forecast, by Drug Type
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 India
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Formulation
7.4.5.2.3 Market size and forecast, by Drug Type
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Formulation
7.4.5.3.3 Market size and forecast, by Drug Type
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 South Korea
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Formulation
7.4.5.4.3 Market size and forecast, by Drug Type
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 Rest of Asia-Pacific
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Formulation
7.4.5.5.3 Market size and forecast, by Drug Type
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Formulation
7.5.3 LAMEA Market size and forecast, by Drug Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Formulation
7.5.5.1.3 Market size and forecast, by Drug Type
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 South Africa
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Formulation
7.5.5.2.3 Market size and forecast, by Drug Type
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 Saudi Arabia
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Formulation
7.5.5.3.3 Market size and forecast, by Drug Type
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Formulation
7.5.5.4.3 Market size and forecast, by Drug Type
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Pfizer Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Sanofi
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck and Company
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GSK
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 johnson and johnson md&d
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Abbott Laboratories
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 CELON LABORATORIES LIMITED
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sun Pharmaceuticals Ltd
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Astellas Pharma Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Cipla Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Blastomycosis Market,' the blastomycosis market size was valued at $177.16 million in 2021, and is estimated to reach $257.7 million by 2031, growing at a CAGR of 3.8% from 2022 to 2031.Blastomycosis is a fungal infection caused by the organism Blastomyces dermatitidis. It causes pulmonary infection after the inhalation of spores, and it may be either asymptomatic or have severe life-threatening complications such as acute respiratory distress syndrome. Primary cutaneous blastomycosis, though rare, can occur due to direct inoculation after trauma to the skin. Unlike other deep fungal infections that occur predominantly in immunocompromised patients, blastomycosis occurs in immunocompetent hosts. In infected cells, blastomycosis dermatitidis is seen as budding yeast cells that are relatively large at 8 to 10 micrometers in diameter.
In blastomycosis, Blastomyces dermatitidis converts to the yeast form, the thick wall of yeast provides resistance to phagocytosis and killing, which can result in symptomatic pulmonary infection. Common sources of blastomycosis outbreaks include soil-damaging activities such as construction, excavation, or outdoor recreation activities such as hunting, fishing, camping near lakes or rivers. The medicines such as azoles, amphotericin B, and echinocandins are used in the form of drug, ointment, and powder for the treatment of blastomycosis.
The COVID-19 outbreak is anticipated to have a negative impact on the blastomycosis market. This was due to the increased risk of severe disease due to compromised immune systems for many individuals. In addition, these patients and the manufacturers of their therapies had to face challenges including ensuring patient access to therapy, supply chain issues and setbacks in research efforts.
Growth of the blastomycosis market share is majorly driven by rise in diagnostic procedure to detect the chronic infection, rise in prevalence of chronic diseases, increase in bone marrow & organ transplantation, increase in hematological cancer cases, and rise in demand for amphotericin B therapy. In addition, rise in cases of immunological diseases, rise in prevalence of blastomycosis and increase in prevalence of human immunodeficiency virus (HIV) fuel Blastomycosis Market Growth.
For instance, according to the Centers for Disease Control and Prevention, the yearly incidence rates of blastomycosis are approximately 1 to 2 cases per 100,000 population in U.S. and Canada. In northern countries such as Russia, and Finland, yearly rates range from 10 to 40 cases per 100,000 persons.
On the basis of formulation, the liquid segment generated maximum revenue in 2021 and is also expected to witness highest CAGR during the forecast period, owing to high adoption of liquid formulation for the treatment of blastomycosis fungal infection and increase in prevalence of fungal infection. In addition, surge in requirement of quick onset of action in treatment of blastomycosis has propelled the growth of liquid segment.
On the basis of drug type, the azoles segment generated maximum revenue in 2021, and is also expected to witness highest CAGR during the forecast period, owing to rise in number of fungal infections such as blastomycosis, candidiasis, immunological disease, and rise in awareness regarding use of azole drug for the treatment of blastomycosis. The growth of azoles segment is also associated with increase in use of azole drug in combination with other drug for synergistic effect.
On the basis of distribution channel, the online pharmacy segment is expected to witness highest CAGR during the forecast period, owing to increase in discounted rates for patients, increase in convenience in shopping, continuous services for providing blastomycosis medicine, and availability of a wide range of options for purchasing medicine.
Depending on region, LAMEA is expected to witness highest CAGR during the forecast period, owing to increase in populations, rise in prevalence of immunological diseases such as tuberculosis, HIV diseases, and rise in awareness regarding use of azoles for the treatment of blastomycosis.
KEY FINDINGS OF THE STUDY
On the basis of type of formulation, the liquid segment held the largest share in the blastomycosis industry in 2021.By drug type, the azoles segment held the largest share in the blastomycosis market in 2021.
Extensive analysis of the market based on procedures and services assists to understand the Blastomycosis market trends in the industry.
On the basis of distribution channel, the hospital and clinical pharmacy segment held the largest market share in 2021.
On the basis of region, North America held the largest market share in 2021
Companies Mentioned
- Pfizer Inc.
- Sanofi
- Merck and Company
- Gsk
- Johnson and Johnson Md&D
- Abbott Laboratories
- Celon Laboratories Limited
- Sun Pharmaceuticals Ltd.
- Astellas Pharma Inc.
- Cipla Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
